GO:0001814 negative regulation of antibody-dependent cellular cytotoxicity: Immune Evasion Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001814 describes any process that stops, prevents, or reduces the rate of antibody-dependent cellular cytotoxicity (ADCC).
• ADCC is an immune effector mechanism in which Fc receptor-bearing effector cells kill antibody-coated target cells.
• Negative regulation of ADCC is exploited by pathogens and tumors to evade antibody-mediated killing.
• Key molecular players include Fcγ receptors such as FCGR3B (CD16b), HLA-DR, CD4, and mTOR signaling [3,6,8].
• Therapeutic antibodies such as anti-CCR4 and anti-Claudin18.2 rely on ADCC, so understanding its negative regulation is clinically important [1,5].
• CRISPR knockout, knock-in, and overexpression models enable causal dissection of negative regulators of ADCC.
Description
Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism by which therapeutic antibodies and natural immunity eliminate target cells. In ADCC, antibodies bind antigens on target cells and engage Fc gamma receptors (FcγRs) on effector cells such as natural killer cells, monocytes, and neutrophils, triggering target cell death. Because ADCC is potent, organisms have evolved multiple layers of negative regulation to prevent excessive tissue damage and to allow pathogens and tumors to evade immune attack. GO:0001814, negative regulation of antibody-dependent cellular cytotoxicity, captures these inhibitory processes. Understanding this GO term is essential for researchers optimizing antibody therapeutics, studying tumor immune evasion, and dissecting host-pathogen interactions [3,5]. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the mechanisms, genes, diseases, and experimental models associated with GO:0001814.
negative regulation of antibody-dependent cellular cytotoxicity At A Glance
| GO ID | GO:0001814 |
|---|---|
| GO term | negative regulation of antibody-dependent cellular cytotoxicity |
| Ontology | biological_process |
| Synonym | down regulation of antibody-dependent cellular cytotoxicity; inhibition of antibody-dependent cellular cytotoxicity; negative regulation of antibody-dependent cell killing |
| Major function | Dampening or preventing ADCC-mediated target cell killing |
| Related process | Regulation of immune effector cell function; Fc receptor signaling |
| Cellular context | Effector cells (NK cells, monocytes, neutrophils) and antibody-coated target cells |
| Disease relevance | Tumor immune evasion, HIV-1 persistence, transplantation, autoimmune conditions |
What Is GO:0001814?
GO:0001814 (negative regulation of antibody-dependent cellular cytotoxicity) is a biological process defined as any process that stops, prevents, or reduces the rate of antibody-dependent cellular cytotoxicity. In other words, it encompasses molecular and cellular events that dampen or block the killing of antibody-coated target cells by Fc receptor-bearing effector cells. This regulation can occur at the level of antibody recognition, Fc receptor availability, effector cell activation, or target cell susceptibility [3,6,8].
Why Is negative regulation of antibody-dependent cellular cytotoxicity Important in Cell Biology?
Negative regulation of ADCC is critically important because it determines the efficacy of antibody-based therapies and influences outcomes in infectious disease and cancer. For example, HIV-1-infected cells downregulate CD4 to evade ADCC mediated by non-neutralizing antibodies, directly linking negative regulation of ADCC to viral persistence. In cancer, FcγRIIIb on neutrophils restricts antibody-dependent destruction of cancer cells, highlighting a negative regulatory role for this receptor. Therapeutic antibodies such as anti-CCR4 and zolbetuximab rely on ADCC for clinical activity, so understanding how ADCC is negatively regulated can guide antibody engineering and combination strategies [1,5]. Moreover, negative regulation of ADCC can protect against autoimmunity but may also limit tumor immunosurveillance [6,7].
• Determines the potency of therapeutic antibodies that work through ADCC [1,5].
• Enables HIV-1 to evade non-neutralizing antibody responses by downregulating CD4.
• FcγRIIIb on neutrophils restricts antibody-dependent cancer cell destruction.
• mTOR inhibition and anti-blood group A/B antibody ligation negatively regulate HLA-DR expression, impacting immune recognition.
• Modulates macrophage-mediated antibody-dependent cellular phagocytosis in cancer immunotherapy.
• Relevant to transplantation immunology and graft rejection.
• Provides targets for enhancing antibody therapy efficacy by blocking negative regulators.
• Helps explain variability in clinical responses to monoclonal antibodies.
• Guides development of next-generation antibodies with optimized Fc engineering.
• Supports research on autoimmune diseases where ADCC contributes to tissue damage.
What Happens During negative regulation of antibody-dependent cellular cytotoxicity?
Reduced antibody recognition of target cells
In simple terms: If antibodies cannot bind well to the target cell, ADCC cannot start.
Negative regulation of ADCC can occur when target cells reduce expression of the antigen recognized by the antibody or when antibodies are outcompeted. In HIV-1 infection, downregulation of CD4 on infected cells precedes Env expression and protects these cells from ADCC mediated by non-neutralizing antibodies. This antigen loss or masking effectively stops ADCC before it begins.
Modulation of Fc receptor availability or function
In simple terms: Effector cells need Fc receptors to grab antibodies; if those receptors are blocked or downregulated, killing is reduced.
Fc gamma receptors (FcγRs) on effector cells are essential for ADCC. Negative regulation can occur through altered expression or inhibitory FcγR signaling. FcγRIIIb (CD16b) on human neutrophils has been shown to restrict antibody-dependent destruction of cancer cells, acting as a negative regulator of ADCC. This demonstrates that specific Fc receptor isoforms can dampen effector function.
Inhibition of effector cell activation signaling
In simple terms: Even if antibodies and receptors engage, the effector cell's internal activation signals can be blocked.
Intracellular signaling pathways in effector cells can be targeted to reduce ADCC. For instance, mTOR inhibition negatively regulates HLA-DR expression on endothelial cells following anti-blood group A/B antibody ligation, which may impact immune recognition and effector interactions. Such signaling modulation can reduce the activation of effector cells required for ADCC.
Target cell resistance to cytotoxic payloads
In simple terms: Target cells can become resistant to the killing machinery delivered by effector cells.
Negative regulation of ADCC can also occur at the level of target cell susceptibility to apoptosis or lysis. Although specific mechanisms are less defined, the balance between pro-apoptotic and anti-apoptotic signals in target cells can determine whether ADCC proceeds. This layer of regulation is relevant in cancer, where tumor cells may acquire resistance to immune-mediated killing.
Phagocytosis versus cytotoxicity balance
In simple terms: Macrophages can either eat or kill target cells; shifting this balance can negatively regulate ADCC.
Antibody-dependent cellular phagocytosis (ADCP) is a related mechanism. Promoting ADCP can sometimes reduce cytotoxic ADCC by diverting effector cells toward phagocytosis. Cao et al. discuss strategies to promote ADCP for cancer immunotherapy, implying that the balance between ADCP and ADCC is subject to regulation. Negative regulation of ADCC may involve favoring phagocytic pathways over cytotoxic ones.
Key Genes Involved in GO:0001814 negative regulation of antibody-dependent cellular cytotoxicity
The following genes and proteins have been implicated in the negative regulation of antibody-dependent cellular cytotoxicity, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD4 | Downregulation on HIV-1-infected cells protects from ADCC | HIV-1 immune evasion |
| FCGR3B | FcγRIIIb on neutrophils restricts antibody-dependent cancer cell destruction | Negative regulator of ADCC in cancer |
| HLA-DR | Expression negatively regulated by anti-blood group A/B antibody ligation and mTOR inhibition | Transplantation immunology |
| MTOR | Inhibition reduces HLA-DR expression, impacting immune recognition | Signaling pathway in negative regulation |
| CCR4 | Target of anti-CCR4 monoclonal antibody; ADCC-dependent therapy | Clinical application in lymphoma |
| CLDN18.2 | Target of zolbetuximab; ADCC contributes to efficacy | Gastric/gastroesophageal junction cancer |
| TROP2 | Target of sacituzumab govitecan; ADCC may contribute to activity | Pancreatic, gastric, and other cancers |
| FCGR3A | Activating FcγRIIIa on NK cells; positive regulator of ADCC | Effector cell function |
| FCGR2B | Inhibitory FcγRIIb; potential negative regulator of ADCC | Effector cell inhibition |
| ENV | HIV-1 envelope protein; expression timing affects ADCC susceptibility | HIV-1 pathogenesis |
| LDH | Lactate dehydrogenase release used to measure ADCC | ADCC assay methodology |
| SN-38 | Topoisomerase inhibitor payload in sacituzumab govitecan | Antibody-drug conjugate |
| CD16 | FcγRIII (FCGR3A/B); mediates ADCC and its regulation | Effector cell receptor |
| NK cells | Primary effector cells for ADCC | Cellular immunity |
| Macrophages | Effector cells for ADCP and ADCC | Cancer immunotherapy |
| Neutrophils | Effector cells with FcγRIIIb that can restrict ADCC | Cancer cell destruction |
How Is negative regulation of antibody-dependent cellular cytotoxicity Regulated?
Negative regulation of ADCC is controlled at multiple levels. mTOR signaling inhibition can reduce HLA-DR expression on endothelial cells after anti-blood group A/B antibody ligation, thereby modulating immune recognition. In HIV-1 infection, the viral protein Env and host CD4 downregulation create a window where infected cells are protected from ADCC mediated by non-neutralizing antibodies. FcγRIIIb on neutrophils acts as a negative regulator by restricting antibody-dependent destruction of cancer cells. Additionally, the balance between activating and inhibitory FcγRs on effector cells determines the net ADCC response. These regulatory layers ensure that ADCC is tightly controlled to avoid collateral damage.
negative regulation of antibody-dependent cellular cytotoxicity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CD4 | HIV-1 immune evasion | CD4 knockout or knockdown in HIV-1-infected cell lines |
| FCGR3B | Cancer resistance to antibody therapy | FCGR3B overexpression in neutrophil-like cells |
| HLA-DR | Transplant rejection | HLA-DR knockout endothelial cells |
| MTOR | Transplant immunology | MTOR knockout or inhibitor-treated cells |
| CCR4 | Adult T-cell leukemia/lymphoma | CCR4 knockout lymphoma cells |
HIV-1 immune evasion
HIV-1-infected cells downregulate CD4 before Env expression, which protects them from ADCC mediated by non-neutralizing antibodies. This negative regulation of ADCC contributes to viral persistence and reservoir establishment, making it a target for therapeutic intervention.
Cancer immunotherapy resistance
FcγRIIIb on human neutrophils restricts antibody-dependent destruction of cancer cells, representing a mechanism of resistance to antibody therapies. Tumors may also exploit negative regulation of ADCC to evade monoclonal antibody treatments such as anti-CCR4 or zolbetuximab [1,5]. Understanding these pathways can inform combination strategies to enhance ADCC.
Transplantation and autoimmunity
Negative regulation of ADCC can be protective in transplantation by limiting antibody-mediated damage. Anti-blood group A/B antibody ligation with mTOR inhibition negatively regulates HLA-DR expression on endothelial cells, which may reduce immune activation. In autoimmunity, dampening ADCC may prevent tissue destruction, but it can also impair tumor surveillance.
From negative regulation of antibody-dependent cellular cytotoxicity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CD4 downregulation protect HIV-1-infected cells from ADCC? | CD4 knockout in HIV-1-infected T cell lines |
| Does FCGR3B inhibit ADCC in neutrophils? | FCGR3B overexpression in neutrophil-like HL-60 cells |
| Does mTOR inhibition reduce HLA-DR expression? | MTOR knockout endothelial cells |
| Can blocking inhibitory FcγR enhance ADCC? | FCGR2B knockout macrophages |
| Does CCR4 expression affect anti-CCR4 ADCC? | CCR4 knockout or overexpression in T cell lines |
| Does Claudin18.2 level influence zolbetuximab ADCC? | CLDN18.2 knockout gastric cancer cells |
How to Study the negative regulation of antibody-dependent cellular cytotoxicity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LDH release assay | Target cell lysis | Quantifying ADCC |
| Reporter ADCC assay | FcγR activation | High-throughput screening |
| Flow cytometry | Surface FcγR and antigen levels | Effector/target cell profiling |
| CRISPR knockout screen | Gene function in ADCC | Identifying negative regulators |
| Western blot | Protein expression and phosphorylation | Signaling pathway analysis |
| ELISA | Cytokine release | Effector cell activation |
| Phagocytosis assay | ADCP activity | Macrophage function |
ADCC reporter assays
ADCC is commonly measured using lactate dehydrogenase (LDH) release assays, which quantify target cell lysis. Reporter-based assays using FcγR-expressing effector cells and luciferase readouts are also widely used. These methods allow precise quantification of negative regulation by candidate genes.
Flow cytometry and Fc receptor profiling
Flow cytometry can assess surface expression of FcγRs (e.g., FCGR3A, FCGR3B) and target antigens on effector and target cells. This is critical for understanding how negative regulators alter receptor availability.
CRISPR screening for regulators
Genome-wide CRISPR knockout screens can identify genes whose loss enhances or suppresses ADCC. Such screens have revealed negative regulators like FCGR3B and signaling components. Bioinformatics analysis of screen hits can uncover pathways enriched in GO:0001814.
Western blot and phospho-signaling analysis
Western blotting for phosphorylated signaling proteins (e.g., mTOR targets) can reveal how negative regulators modulate effector cell activation. This complements functional ADCC assays.
How CRISPR Can Be Used to Study GO:0001814 negative regulation of antibody-dependent cellular cytotoxicity
Knockout
CRISPR knockout of candidate negative regulators such as FCGR3B or CD4 can enhance ADCC, validating their inhibitory role [3,8]. Knockout cell lines are essential for causal studies.
Point Mutation
Point mutations in FcγR genes (e.g., FCGR3A V158F) can alter ADCC potency. CRISPR point mutation models allow precise testing of these variants in isogenic backgrounds.
Knock-in
Knock-in of human FcγR genes into mouse models can humanize ADCC pathways for in vivo studies. This is valuable for testing antibody therapeutics [1,5].
Overexpression
Overexpression of negative regulators like FCGR3B or HLA-DR can suppress ADCC, providing gain-of-function evidence [6,8]. Such models help quantify the strength of inhibition.
How EDITGENE Supports negative regulation of antibody-dependent cellular cytotoxicity Research
Researchers studying negative regulation of antibody-dependent cellular cytotoxicity-related genes often need to determine whether a candidate gene is causally involved in dampening ADCC. This requires precise genetic models that can knockout, mutate, knock-in, or overexpress the gene of interest in relevant effector or target cells. EDITGENE provides end-to-end CRISPR services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of antibody-dependent cellular cytotoxicity research.
Frequently Asked Questions About negative regulation of antibody-dependent cellular cytotoxicity
What is negative regulation of antibody-dependent cellular cytotoxicity?
It is any process that stops, prevents, or reduces the rate of ADCC, as defined by GO:0001814.
What genes are involved in negative regulation of ADCC?
Genes such as CD4, FCGR3B, HLA-DR, and MTOR have been implicated in negative regulation of ADCC [3,6,8].
How is ADCC measured in the lab?
ADCC is often measured using lactate dehydrogenase (LDH) release assays or reporter-based assays.
Why do tumors evade ADCC?
Tumors can exploit negative regulators like FcγRIIIb on neutrophils to restrict antibody-dependent destruction.
How does HIV-1 evade ADCC?
HIV-1-infected cells downregulate CD4, protecting them from ADCC mediated by non-neutralizing antibodies.
What is the role of mTOR in ADCC regulation?
mTOR inhibition can negatively regulate HLA-DR expression, impacting immune recognition.
Can CRISPR be used to study negative regulation of ADCC?
Yes, CRISPR knockout or overexpression of candidate genes can validate their role in ADCC regulation.
What is the difference between ADCC and ADCP?
ADCC involves cytotoxic killing, while ADCP involves phagocytosis; the balance can be regulated.
Which therapeutic antibodies rely on ADCC?
Anti-CCR4 and zolbetuximab are examples of antibodies whose efficacy involves ADCC [1,5].
What cell types are effector cells in ADCC?
NK cells, monocytes, macrophages, and neutrophils can act as effector cells [4,8].
Conclusion
GO:0001814, negative regulation of antibody-dependent cellular cytotoxicity, is a critical biological process that modulates the potency of antibody-based immunity. Key negative regulators include CD4, FCGR3B, HLA-DR, and mTOR, with implications for HIV-1 evasion, cancer immunotherapy resistance, and transplantation [3,6,8]. Understanding these mechanisms can guide the development of next-generation antibody therapeutics and combination strategies. EDITGENE offers comprehensive CRISPR services to dissect these pathways and accelerate translational research.
References
- 1. Kubota Y et al.. 2024. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.. Ther Adv Med Oncol 16:17588359231217967 PMID: 38188462
- 2. Cardillo TM et al.. 2015. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.. Bioconjug Chem 26(5):919-31 PMID: 25915780
- 3. Richard J et al.. 2024. CD4 downregulation precedes Env expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing antibodies.. mBio 15(11):e0182724 PMID: 39373535
- 4. Broussas M et al.. 2013. Evaluation of antibody-dependent cell cytotoxicity using lactate dehydrogenase (LDH) measurement.. Methods Mol Biol 988:305-17 PMID: 23475728
- 5. Ueda R. 2015. Clinical Application of Anti-CCR4 Monoclonal Antibody.. Oncology 89 Suppl 1:16-21 PMID: 26550987
- 6. Iwasaki K et al.. 2017. Negative regulation of HLA-DR expression on endothelial cells by anti-blood group A/B antibody ligation and mTOR inhibition.. Transpl Immunol 40:22-30 PMID: 28017877
- 7. Cao X et al.. 2022. Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy.. Sci Adv 8(11):eabl9171 PMID: 35302839
- 8. Treffers LW et al.. 2018. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.. Front Immunol 9:3124 PMID: 30761158
